182400 — NKGen Biotech Korea Co Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.27% | ||
| Return on Equity | 17.88% | ||
| Operating Margin | -27.31% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 10,371.55 | 13,020.25 | 11,262.69 | 10,769.16 | 8,800.04 | n/a | n/a | 0.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NKGen Biotech Korea Co Ltd, formerly NKMax Co Ltd is a Korea-based company primarily engaged in the research, development, manufacturing, and supply of biological products. The company operates immune cell therapy, immunodiagnostic kits, health functional food sales, and bioresearch reagent businesses.
Directors
- Sang Wu Park CEO (46)
- Yong Hwan Cho MDR (43)
- Jong Yun Lee OTH (46)
- Wu Sik Choi DRC (46)
- Gyeong Mo Gu DRC (36)
- Seung Ju Hahm DRC (49)
- Pierre Kang Yong DRC (43)
- Jong Seon Kim DRC (52)
- Jae Myeon Lee DRC (48)
- Cheong Gyo Park DRC (54)
- Ho Geun Yoon DRC (45)
- Jae Ho Jung NID (45)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- January 14th, 2002
- Public Since
- October 23rd, 2015
- No. of Shareholders
- 44,835
- No. of Employees
- 86
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 71,377,414.37
- Address
- 440, Changnyong-daero, Yeongtong-gu, SUWON, 16504
- Web
- https://nkmax.com/kor/
- Phone
- +82 316039218
- Auditors
- Daejoo Accounting Corp.
FAQ
What is the NKGen Biotech Korea Co share price?
As of Today at 12:21 UTC, shares in NKGen Biotech Korea Co are trading at KR₩3,685. This share price information is delayed by 15 minutes.
How has the NKGen Biotech Korea Co share price performed this year?
Shares in NKGen Biotech Korea Co last closed at KR₩3,685 and the price had moved by -61.34% over the past 365 days. In terms of relative price strength the NKGen Biotech Korea Co share price has underperformed the FTSE Developed Asia Pacific Index by -74.59% over the past year.
What are the analyst and broker recommendations for NKGen Biotech Korea Co?
There is no consensus recommendation for this security.
Find out moreWhat is the NKGen Biotech Korea Co dividend yield?
NKGen Biotech Korea Co does not currently pay a dividend.
Does NKGen Biotech Korea Co pay a dividend?
NKGen Biotech Korea Co does not currently pay a dividend.
When does NKGen Biotech Korea Co next pay dividends?
NKGen Biotech Korea Co does not currently pay a dividend.
How do I buy NKGen Biotech Korea Co shares?
To buy shares in NKGen Biotech Korea Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NKGen Biotech Korea Co?
As of the previous close price of KR₩3,685, shares in NKGen Biotech Korea Co had a market capitalisation of .
Where are NKGen Biotech Korea Co shares listed?
Here are the trading details for NKGen Biotech Korea Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 182400
What kind of share is NKGen Biotech Korea Co?
Based on an overall assessment of its quality, value and momentum NKGen Biotech Korea Co is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NKGen Biotech Korea Co share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the NKGen Biotech Korea Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NKGen Biotech Korea Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -76.67%.
As of the last closing price of KR₩3,685, shares in NKGen Biotech Korea Co were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NKGen Biotech Korea Co PE Ratio?
The NKGen Biotech Korea Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩3,685.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NKGen Biotech Korea Co?
NKGen Biotech Korea Co's management team is headed by:
- Sang Wu Park - CEO
- Yong Hwan Cho - MDR
- Jong Yun Lee - OTH
- Wu Sik Choi - DRC
- Gyeong Mo Gu - DRC
- Seung Ju Hahm - DRC
- Pierre Kang Yong - DRC
- Jong Seon Kim - DRC
- Jae Myeon Lee - DRC
- Cheong Gyo Park - DRC
- Ho Geun Yoon - DRC
- Jae Ho Jung - NID